BioCentury | Sep 14, 2015
Company News

Breckenridge sales and marketing update

...least five years old and vasomotor rhinitis in patients ages at least 12 years old. Breckenridge Pharmaceutical Inc....
BioCentury | Jul 14, 2014
Company News

Breckenridge Pharmaceutical Inc, Teva, Natco cancer news

...Breckenridge and partner Natco in the U.S. District Court for the District of Delaware alleging Breckenridge’s...
...IV certification saying that the patents are invalid, unenforceable and/or would not be infringed by Breckenridge’s...
...expires in October 2030 and the ‘863 patent expires in January 2026. In its response, Breckenridge...
BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Cancer

...doi:10.1038/scibx.2012.1252 Published online Dec. 13, 2012 rQNestin34.5 patented by Massachusetts General Hospital; available for licensing Alvarez-Breckenridge...
BioCentury | Jan 3, 2011
Company News

Breckenridge Pharmaceuticals Inc., Synthon Pharmaceuticals Inc., Watson, Aurobindo, Dr. Reddy's, Mylan, Novartis, Ranbaxy, Takeda, Teva, Torrent, Wockhardt endo

...billion for its FY10 ending March 31. Takeda's patents for the products expire in 2016. Breckenridge...
BioCentury | Jan 28, 2008
Clinical News

Sirtris preclinical data

...of mitochondria. Data were presented at the Diabetes Mellitus, Insulin Action and Resistance meeting in Breckenridge...
BioCentury | Jan 28, 2008
Clinical News

Genaera preclinical data

...hormone expression. Data were presented at the Diabetes Mellitus, Insulin Action and Resistance meeting in Breckenridge...
BioCentury | Feb 5, 2007
Clinical News

Compugen preclinical data

...inhibits the MCP-1/ CCR2 pathway. Data were presented at the Cytokines and Inflammation meeting in Breckenridge...
BioCentury | Jan 17, 2005
Clinical News

Alnylam preclinical data

...that were treated with a saline control. Data were presented at the Keystone Symposium in Breckenridge...
BioCentury | Jan 17, 2005
Clinical News

Alnylam preclinical data

...RNAs (siRNAs) specifically inhibited RSV infection. Data were presented at the Keystone Symposium meeting in Breckenridge...
Items per page:
1 - 9 of 9
BioCentury | Sep 14, 2015
Company News

Breckenridge sales and marketing update

...least five years old and vasomotor rhinitis in patients ages at least 12 years old. Breckenridge Pharmaceutical Inc....
BioCentury | Jul 14, 2014
Company News

Breckenridge Pharmaceutical Inc, Teva, Natco cancer news

...Breckenridge and partner Natco in the U.S. District Court for the District of Delaware alleging Breckenridge’s...
...IV certification saying that the patents are invalid, unenforceable and/or would not be infringed by Breckenridge’s...
...expires in October 2030 and the ‘863 patent expires in January 2026. In its response, Breckenridge...
BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Cancer

...doi:10.1038/scibx.2012.1252 Published online Dec. 13, 2012 rQNestin34.5 patented by Massachusetts General Hospital; available for licensing Alvarez-Breckenridge...
BioCentury | Jan 3, 2011
Company News

Breckenridge Pharmaceuticals Inc., Synthon Pharmaceuticals Inc., Watson, Aurobindo, Dr. Reddy's, Mylan, Novartis, Ranbaxy, Takeda, Teva, Torrent, Wockhardt endo

...billion for its FY10 ending March 31. Takeda's patents for the products expire in 2016. Breckenridge...
BioCentury | Jan 28, 2008
Clinical News

Sirtris preclinical data

...of mitochondria. Data were presented at the Diabetes Mellitus, Insulin Action and Resistance meeting in Breckenridge...
BioCentury | Jan 28, 2008
Clinical News

Genaera preclinical data

...hormone expression. Data were presented at the Diabetes Mellitus, Insulin Action and Resistance meeting in Breckenridge...
BioCentury | Feb 5, 2007
Clinical News

Compugen preclinical data

...inhibits the MCP-1/ CCR2 pathway. Data were presented at the Cytokines and Inflammation meeting in Breckenridge...
BioCentury | Jan 17, 2005
Clinical News

Alnylam preclinical data

...that were treated with a saline control. Data were presented at the Keystone Symposium in Breckenridge...
BioCentury | Jan 17, 2005
Clinical News

Alnylam preclinical data

...RNAs (siRNAs) specifically inhibited RSV infection. Data were presented at the Keystone Symposium meeting in Breckenridge...
Items per page:
1 - 9 of 9